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ate Incomplete Stent Apposition
fter Sirolimus-Eluting Stent Implantation
Serial Intravascular Ultrasound Analysis
unya Ako, MD,* Yoshihiro Morino, MD,* Yasuhiro Honda, MD, FACC,* Ali Hassan, MD,*
hinjo Sonoda, MD, PHD,* Paul G. Yock, MD, FACC,* Martin B. Leon, MD, FACC,†
effrey W. Moses, MD, FACC,† Heidi N. Bonneau, RN, MS,‡ Peter J. Fitzgerald, MD, PHD, FACC*
tanford and San Jose, California; and New York, New York
OBJECTIVES We sought to identify the frequency of incomplete stent apposition (ISA) in sirolimus-eluting
stents (SES) and clarify its findings and clinical sequelae.
BACKGROUND Late-acquired ISA has been reported in bare-metal stents (BMS) and brachytherapy and
recently in drug-eluting stents. However, the characteristics of late ISA in SES have not been
clarified.
METHODS From the SIRIUS trial, a randomized, multicenter study comparing SES and BMS, serial
qualitative intravascular ultrasound (IVUS; at stent implantation and eight-month follow-up)
was available in 141 patients (BMS: n  61; SES: n  80). The IVUS images were reviewed
for the presence of ISA.
RESULTS Incomplete stent apposition at follow-up was observed in 19 patients (BMS: n  6 [9.8%];
SES: n 13 [16.3%]; pNS). Among these, 12 had ISA after intervention and at follow-up
(persistent ISA). Late-acquired ISA was seen in the remaining seven cases, all from the SES
group (BMS: n  0; SES: n  7 [8.7%]; p  0.05). In late-acquired ISA, there was an
increase in external elastic membrane area (after intervention: 16.2 2.7 m2; follow-up: 18.9
3.6 mm2; p  0.05). The location of stent-vessel wall separation was primarily at the stent
edges in persistent ISA cases, whereas late-acquired ISA in SES occurred mostly in the mid
portion of the stent. There were no negative clinical events reported for any ISA cases at
12-month clinical follow-up.
CONCLUSIONS Late ISA was observed in 8.7% of patients after SES implantation. There were no negative
clinical events associated with this IVUS finding at 12-month clinical follow-up; however,
careful long-term follow-up will be necessary. (J Am Coll Cardiol 2005;46:1002–5) © 2005
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.068by the American College of Cardiology Foundation
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an recent years, stent-based local drug delivery has
merged as a promising technology to reduce restenosis.
everal clinical studies have shown that drug-eluting stents
DES) achieve a striking inhibition of neointimal hyperpla-
ia (1–6).
Drug-eluting stents, as well as intravascular brachyther-
py, target several mechanisms to decrease proliferation of
ascular smooth muscle cells, which contribute to the
estenotic process. However, intravascular brachytherapy
as later associated with a considerably high incidence of
ate thrombosis, complicating the clinical outcomes (7,8).
hrough the use of intravascular ultrasound (IVUS), several
nusual observations, including unhealed stent edge dissec-
ions and incomplete stent apposition (ISA), were made
fter brachytherapy (9,10). This unusual IVUS finding has
eceived much attention, given the concern that ISA could
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ccepted May 31, 2005.ossibly contribute to one of the factors related to throm-
osis (8,11). To date, the incidence of incomplete apposi-
ion in DES, however, has not been well investigated. Thus,
he aim of our study was to identify the frequency of ISA in
irolimus-eluting stents (SES) and clarify its findings and
linical sequelae.
ETHODS
tudy population and protocol. The study population
onsisted of patients with completed serial IVUS analysis
rom the Sirolimus-Eluting Stent in De Novo Coronary
esions (SIRIUS) trial (12), a multicenter, randomized,
ouble-blind study that evaluated the safety and effective-
ess of the sirolimus-coated Bx Velocity stent compared
ith the uncoated Bx Velocity balloon-expandable stent
Cordis Corp., Warren, New Jersey) in de novo native
oronary artery lesions. At 16 sites, IVUS was performed
fter the procedure and at eight-month follow-up. Lesions
15 mm and 30 mm in length and vessels 2.5 mm and
3.5 mm in diameter were included. Multiple stent use was
llowed as needed at the operator’s discretion. Two types of
tent length (8 and 18 mm) were available for both groups,
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September 20, 2005:1002–5 Incomplete Stent Appositionith diameter line-ups of 2.5, 3.0, and 3.5 mm. Protocols
ere approved by the local human subjects committee in all
articipating institutions, and all patients gave written,
nformed consent.
VUS imaging and analysis. After administration of in-
racoronary nitroglycerin, IVUS images were acquired using
ommercially available imaging systems with automated
ransducer pullback (0.5 mm/s). The IVUS images were
nterpreted at an independent core laboratory (Stanford
ardiovascular Core Analysis Laboratory) blinded to the
reatment protocols.
Qualitative analysis involved review of all IVUS tapes for
he presence of ISA. Incomplete stent apposition was
efined as one or more stent struts clearly separated from
he vessel wall with evidence of blood speckles behind the
trut in a vessel segment not associated with any side
ranches. Resolved ISA was defined as ISA observed at
aseline but not at follow-up. Persistent ISA was defined as
SA observed both at baseline and follow-up. Late-acquired
SA was defined as ISA observed at follow-up but not at
aseline. Typical IVUS images of late-acquired ISA are
hown in Figures 1 and 2. The adjudication of the opinions
as based on the consensus of three independent analysts
J. A., Y. H., and S. S.).
Quantitative analysis was performed using computerized
lanimetry (TapeMeasure, Indec Systems Inc., Mountain
iew, California). Quantitative measurements of incom-
letely apposed sections included the external elastic mem-
rane (EEM), stent, and lumen area. The angle of ISA was
Abbreviations and Acronyms
BMS  bare-metal stent
DES  drug-eluting stent
EEM  external elastic membrane
ISA  incomplete stent apposition
IVUS  intravascular ultrasound
SES  sirolimus-eluting stent
SIRIUS  Sirolimus-Eluting Stent in De Novo
Coronary Lesions study
igure 1. Intravascular ultrasound images of sirolimus-eluting stents with
ate incomplete stent apposition (A) after stent implantation and (B) at
ight-month follow-up. The stent was well apposed to the vessel wall at the
ime of implantation. eeasured using an electronic protractor centered on the
umen. We also measured the baseline plaque thickness
orresponding to the apposed and non-apposed wall seg-
ents. Quantitative measurements were performed at the
rea of greatest stent-lumen separation at follow-up IVUS
maging and matched with the corresponding image from
fter the intervention.
tatistical analysis. Statistical analysis was performed us-
ng StatView 5.0 (SAS Institute Inc., Cary, North Caro-
ina). Continuous data are presented as the mean value 
D, and categorical data are presented as frequencies.
ontinuous variables between persistent ISA and late-
cquired ISA were compared by use of the unpaired Student
test; otherwise, the paired Student t test was used for
omparing continuous variables. Categorical variables were
ompared using chi-square statistics or the Fisher exact test.
he Fisher exact test was used if there was an expected cell
alue 5. Significance was assumed at a value of p  0.05.
ESULTS
total of 1,101 patients were enrolled in the SIRIUS trial,
ith serial qualitative IVUS analyses available in 141 pa-
ients (bare-metal stents [BMS]: n  61; SES: n  80).
able 1 summarizes the frequency of ISA in the SIRIUS trial.
t follow-up, ISA was observed in 19 patients (BMS: n  6
igure 2. Longitudinal images showing late incomplete stent apposition
fter sirolimus-eluting stent implantation: (A) after stent implantation; (B)
t eight-month follow-up. Detachment of the vessel wall (arrows) from
tent strut (dotted lines) was observed in the mid portion of the stent and
n the relatively normal side of the vessel wall.
able 1. Frequency of ISA in BMS and SES
BMS (n  61) SES (n  80)
esolved ISA 3 (4.9%) 7 (8.7%)
ersistent ISA 6 (9.8%) 6 (7.5%)
ate-acquired ISA 0 7 (8.7%)*
p  0.05. Data are presented as the number (%) of subjects.
BMS  bare-metal stents; ISA  incomplete stent apposition; SES  sirolimus-
luting stents.
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Incomplete Stent Apposition September 20, 2005:1002–59.8%]; SES: n  13 [16.3%]; p  NS). A synchronous
omparison between the post-interventional IVUS image and
he follow-up IVUS image showed 12 cases of ISA within
oth vessel segments (persistent ISA) (BMS: n  6 [9.8%];
ES: n  6 [7.5%]; p  NS). The other seven cases, all of
hich were randomized to the SES group, demonstrated
SA only at follow-up (late-acquired ISA). In 10 cases, ISA
bserved at baseline was resolved and was not present at
ollow-up (resolved ISA). In patients with late-acquired
SA, there were six males and one female (ages 56  11
ears), with cardiac risk factors of hypercholesterolemia in
ne (14%), diabetes mellitus in one (14%), and hypertension
n five (71%). In two late-acquired ISA cases, there were
wo loci of stent-vessel separation within one stented
egment.
Among SES, the frequency of late-acquired ISA was
.7% (5 of 57) with single stent implantation and 8.7% (2 of
3) with multiple stent implantations. There was no late-
cquired ISA originating from stent overlap. Three late-
cquired ISA segments showed an increase 20% in EEM,
ncluding one angiographically apparent aneurysm. The
ncreased area for both the EEM and lumen was seen
ithout change in plaque area (Table 2). Seven of nine
ate-acquired ISA segments were directly associated with
he nearly normal vessel walls with thinner baseline plaque
han the opposite arc. The average baseline plaque was
hinner on the non-apposed side than on the opposite side
0.47  0.28 mm vs. 1.1 0.58 mm, respectively; p 0.05).
Table 3 shows comparative data between cases of persis-
ent ISA versus late-acquired ISA. Late-acquired ISA had
reater lumen separation from stent struts, with positive
essel remodeling. The location of stent-vessel wall separa-
ion was primarily at the edges in persistent ISA, whereas
ate-acquired ISA of SES occurred mostly in the mid
ortion of the stent.
ISCUSSION
his serial IVUS comparative study from the SIRIUS trial
dentified an 8.7% incidence of late-acquired ISA seen only
n the SES group. Similarly, the RAndomized study with
he sirolimus-eluting VElocity balloon-expandable stent in
he treatment of patients with de novo native coronary
rtery Lesions (RAVEL) trial reported a 20% incidence of
SA in SES at follow-up (6). However, the RAVEL trial
able 2. Baseline and Follow-Up Intravascular Ultrasound
ross-Sectional Measurements of Late-Acquired Incomplete
tent Apposition
After Intervention Follow-Up
EM (mm2) 16.2  2.7 18.9  3.6*
A (mm2) 8.0  2.0 8.0  2.1
A (mm2) 8.2  1.9 11.0  2.8*n
p  0.05. Values are presented as mean  SD.
EEM  external elastic membrane area; LA  lumen area; PA  plaque area.acked post-stent IVUS analysis; therefore, both late-
cquired ISA and persistent ISA were considered to be
ncluded, contributing to the high incidence reported. In
ur present study, late-acquired ISA did not occur in the
MS group. Late-acquired ISA is reported to occur at a
requency of 1% to 5% with BMS implantation (13,14).
lthough direct comparisons between these studies cannot
e made because of patient differences and multi-device
pproaches (13), our results suggest that ISA occurred with
greater incidence in SES compared with BMS.
The mechanism of late-acquired ISA in SES was mainly
ocal positive vessel remodeling, as previously reported in
MS (14,15). In three ISA segments, there was an increase
20% in vessel area. The plaque area was not significantly
ifferent between post-intervention and follow-up, which
uggests that plaque regression (9), as seen with intravascu-
ar brachytherapy, is not the primary reason for late-
cquired ISA in SES. Incomplete stent apposition was
ainly observed on the relatively disease-free side of the
essel wall (78%), which lends further support to this theory.
ore injury to the vasoelastic normal wall, coupled with a
rug that may delay the healing process, could contribute to
his phenomenon.
The frequency of ISA per patient was quite similar in
oth single and multiple stent cases. In addition, late-
cquired ISA was not seen originating from stent overlap.
hus, late-acquired ISA may not be a dose-dependent event
f sirolimus. From our patient subset, multiple stenting did
ot seem to predispose vessel wall separation from stent
truts; however, studies involving a larger patient population
ay be necessary to confirm this observation.
Previous reports demonstrated ISA at the edges of the
tent in intravascular brachytherapy (16), as well as ISA
fter BMS implantation (13). In the present study, late-
cquired ISA in SES largely occurred in the mid portion of
he stent. The location within the stent, distinct from
revious reports, characterizes late-acquired ISA with SES,
n agreement with the results of the RAVEL trial. The
ifferent locations of ISA indicate involvement of different
iologic processes in the focal positive remodeling and
ubsequent development of ISA in SES. It is intriguing to
able 3. Persistent and Late-Acquired ISA
Persistent
ISA
Late-Acquired
ISA p Value
ap, mm 0.4  0.1 0.7  0.3 0.05
rc (°) 103  19 145  53 0.05
ollow-up LA, mm2 9.0  2.2 11.0  2.9 NS
ollow-up EEM, mm2 17.9  5.7 18.9  3.6 NS
EEM, mm2 0.0  1.4 2.6  3.2 0.05
ocation (%) 0.01
Mid portion 17 78
Stent edges 83 22
alues are presented as mean value  SD or frequencies.
EEM  follow-up EEM  post-intervention EEM; other abbreviations as in
ables 1 and 2.ote that there is relatively less efficacy of neointimal
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September 20, 2005:1002–5 Incomplete Stent Appositionuppression at the edges in SES (17). This asymmetric
istribution of neointimal tissue within the stent may be
ssociated with the location of late-acquired ISA with SES.
ate-acquired ISA may occur due to profound localized
nhibition of neointimal formation in disease-free segments
f the vessel, delaying early reparative events that usually
nable the vessel wall to incorporate a stent. Flow dynamics
n these segments may also favor positive remodeling of the
rtery at sites of delayed neointimal formation, resulting in
ate-acquired ISA.
Incomplete stent apposition at the stent edges provides an
xit for both inward and outward blood flow. On the other
and, there is a hypothetical concern that non-apposed
egments in the middle of the stent may produce a different
lood flow property with its cul-de-sac formation. Despite
ndings of either persistent or late-acquired ISA, no nega-
ive clinical events were associated with these cases at
2-month clinical follow-up. The three-year data from
AVEL trial also fail to show any increase in adverse
ardiac events, despite the high incidence of incomplete
pposition at follow-up (18). It is still unclear whether this
articular IVUS finding may relate to future adverse events.
e have yet to elucidate the natural history of this unusual
VUS finding. However, in view of the increased incidence
f late-acquired ISA in SES, careful long-term follow-up is
arranted.
tudy limitations. First, this study is based on a relatively
mall number of late-acquired ISA cases, raising the
ossibility of selection bias. Second, IVUS is unable to
dentify neointima 100 m in thickness and acellular
roteinaceous material; thus, we are not able to evaluate
e-endothelialization surrounding the stent struts. Third,
here is a lack of evidence on clinical sequelae related to this
articular morphologic IVUS finding.
onclusions. Serial IVUS analysis from the SIRIUS trial
ound an 8.7% incidence of late ISA after SES implanta-
ion, with late ISA being observed primarily in the middle
f the stent. Despite freedom from clinical events, careful
ong-term follow-up may be necessary, especially in a case
nvironment that may have variable antiplatelet therapy.
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